{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-22-005479","form_type":"8-K","ticker":"GTHP","cik":"0000924515","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2022-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.666665+00:00","generated_at":"2026-06-24T07:11:21.279202+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Guided Therapeutics cancels previously approved 1-for-20 reverse stock split, renders amendment void","bullets":["Certificate of Correction filed July 25, 2022, nullifies December 30, 2021 reverse split amendment ab initio.","FINRA never declared the reverse split effective, so it was never implemented on the OTC Market.","Reverse stock split ratio of up to 1-for-20 was approved by stockholders in July 2021 and board in December 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-22-005479","json":"https://secwatch.observer/filing/0001477932-22-005479.json","markdown":"https://secwatch.observer/filing/0001477932-22-005479.md","text":"https://secwatch.observer/filing/0001477932-22-005479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/924515/000147793222005479/0001477932-22-005479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/924515/000147793222005479/gthp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:11:21.279202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}